Transition From Acute to Chronic Opioid Use and Chronic Pain

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2030

Conditions
Opioid Use Disorder
Interventions
DRUG

Opioid-free anesthesia

Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and dexmedetomidine (12-20 mcg IV) and ketamine (25-50 mcg) prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, dexmedetomidine and ketamine will be administered as needed. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC).

DRUG

Opioid-based anesthesia

Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and fentanyl 50-100 mcg IV prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, each patient in the opioid group will receive IV-fentanyl (50 - 100 mcg) as needed.

Trial Locations (1)

15232

UPMC Shadyside Hospital, Pittsburgh

All Listed Sponsors
lead

Jacques E. Chelly

OTHER

NCT07211399 - Transition From Acute to Chronic Opioid Use and Chronic Pain | Biotech Hunter | Biotech Hunter